Search research articles
Contact Us
Filters
Showing results (11-20 of 52) with videos related to
Page
of 6
Sort By:
British Journal of Haematology
|
January 4, 2024
Busulfan, melphalan and carfilzomib high-dose chemotherapy and autologous haematopoietic stem cell transplantation in multiple myeloma
Patrick Hagen, Joseph Norton, Stephanie Tsai, et al.
The American Journal of Surgical Pathology
|
March 15, 2014
Clinical significance of MYC expression and/or "high-grade" morphology in non-Burkitt, diffuse aggressive B-cell lymphomas: a SWOG S9704 correlative study
James R Cook, Bryan Goldman, Raymond R Tubbs, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
May 19, 2004
Graft-versus-host disease of the skin: life and death on the epidermal edge
Craig C Hofmeister, Adam Quinn, Kenneth R Cooke, et al.
Leukemia & Lymphoma
|
August 31, 2013
Seven-year follow-up of allogeneic transplant using BCNU, etoposide, cytarabine and melphalan chemotherapy in patients with Hodgkin lymphoma after autograft failure: importance of minimal residual disease
Urszula Sobol, Tulio Rodriguez, Scott Smith, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
January 27, 2009
Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient
Patrick Stiff, Ivana Micallef, Philip McCarthy, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 3, 2018
Safety Analysis of Brentuximab Vedotin from the Phase III AETHERA Trial in Hodgkin Lymphoma in the Post-Transplant Consolidation Setting
Auayporn Nademanee, Anna Sureda, Patrick Stiff, et al.
Leukemia & Lymphoma
|
November 21, 2008
Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial
Sucha Nand, John Godwin, Scott Smith, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
January 5, 2010
Randomized phase III trial of pegfilgrastim versus filgrastim after autologus peripheral blood stem cell transplantation
Aaron Gerds, Mary Fox-Geiman, Kevin Dawravoo, et al.
Transplantation and Cellular Therapy
|
November 4, 2023
Exopolysaccharide-Treated Dendritic Cells Effectively Ameliorate Acute Graft-versus-Host Disease
Olga Kalinina, Lisa M Minter, Anne I Sperling, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 15, 2010
Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium
Sonali M Smith, Koen van Besien, Theodore Karrison, et al.
Page
of 6
Search research articles
Search
Showing results (11-20 of 52) with videos related to
Sort By:
Page
of 6
British Journal of Haematology
|
January 4, 2024
Busulfan, melphalan and carfilzomib high-dose chemotherapy and autologous haematopoietic stem cell transplantation in multiple myeloma
Patrick Hagen, Joseph Norton, Stephanie Tsai, et al.
The American Journal of Surgical Pathology
|
March 15, 2014
Clinical significance of MYC expression and/or "high-grade" morphology in non-Burkitt, diffuse aggressive B-cell lymphomas: a SWOG S9704 correlative study
James R Cook, Bryan Goldman, Raymond R Tubbs, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
May 19, 2004
Graft-versus-host disease of the skin: life and death on the epidermal edge
Craig C Hofmeister, Adam Quinn, Kenneth R Cooke, et al.
Leukemia & Lymphoma
|
August 31, 2013
Seven-year follow-up of allogeneic transplant using BCNU, etoposide, cytarabine and melphalan chemotherapy in patients with Hodgkin lymphoma after autograft failure: importance of minimal residual disease
Urszula Sobol, Tulio Rodriguez, Scott Smith, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
January 27, 2009
Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient
Patrick Stiff, Ivana Micallef, Philip McCarthy, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 3, 2018
Safety Analysis of Brentuximab Vedotin from the Phase III AETHERA Trial in Hodgkin Lymphoma in the Post-Transplant Consolidation Setting
Auayporn Nademanee, Anna Sureda, Patrick Stiff, et al.
Leukemia & Lymphoma
|
November 21, 2008
Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial
Sucha Nand, John Godwin, Scott Smith, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
January 5, 2010
Randomized phase III trial of pegfilgrastim versus filgrastim after autologus peripheral blood stem cell transplantation
Aaron Gerds, Mary Fox-Geiman, Kevin Dawravoo, et al.
Transplantation and Cellular Therapy
|
November 4, 2023
Exopolysaccharide-Treated Dendritic Cells Effectively Ameliorate Acute Graft-versus-Host Disease
Olga Kalinina, Lisa M Minter, Anne I Sperling, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 15, 2010
Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium
Sonali M Smith, Koen van Besien, Theodore Karrison, et al.
Page
of 6